prothymosin alpha raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-12. Anything still debated is marked as such rather than presented as settled.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Various theories exist as to whether people who sustain carotid and vertebral artery dissection, even if they do not have a connective tissue disorder, have an underlying vulnerability. Biopsy samples of skin and other arteries has indicated that this might be a possibility, but no genetic defect in collagen or elastin genes has been convincingly proven. Other studies have indicated inflammation of the blood vessels, as measured by highly sensitive C-reactive protein (hsCRP, a marker of inflammation) in the blood. Once dissection has occurred, two mechanisms contribute to the development of stroke symptoms. Firstly, the flow through the blood vessel may be disrupted due to the accumulation of blood under the vessel wall, leading to ischemia (insufficient blood supply). Secondly, irregularities in the vessel wall and turbulence increase the risk of thrombosis (the formation of blood clots) and embolism (migration) of these clots of the brain. From various lines of evidence, it appears that thrombosis and embolism is the predominant problem. Subarachnoid hemorrhage due to arterial rupture typically occurs if the dissection extends into the V4 section of the artery. This may be explained by the fact that the arterial wall is thinner and lacks a number of structural supports in this section.
In this age group, lorazepam is associated with falls and hip fractures. Due to these concerns, lorazepam use is generally recommended for at most four weeks. Lorazepam was initially patented in 1963 and went on sale in the United States in 1977. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 100th most commonly prescribed medication in the United States, with more than 6 million prescriptions.
==== Enantiomeric excesses observed in extraterrestrial amino acids ==== More recently, amino acids from several carbonaceous chondrites have been identified with significant L-enantiomeric excesses. L-excesses from 3–15% in several non-protein α-dialkyl amino acids have been found in the Murchison and Murray meteorites. Their extraterrestrial origin is indicated by their absence in biological systems and significant heavy isotope enrichments in 13C and deuterium compared to terrestrial values. Further characterisation of L-isovaline excesses up to 20.5% in a range of carbonaceous chondrite groups have supported a hypothesis that increasing hydrothermal alteration of the host meteorite correlates with increasing observed L-enantiomeric excess. Large L-excesses for α-H amino acids have also been reported, but these are more problematic due to the potential for terrestrial contamination. The ungrouped C2 chondrite Tagish Lake has L-aspartic acid excesses up to ~60%, with carbon isotope measurements indicating an extraterrestrial origin due to significant enrichments in 13C. In Tagish Lake, proteinogenic amino acids show both significant L-excesses, and racemic mixtures: glutamic acid, serine, and threonine were found to have ~50 – 99% L-excesses, while alanine was racemic. It has been proposed that extraterrestrial amino acid L-excesses observed in carbonaceous chondrites are a result of differences in the crystallisation behaviour of the enantiomers.
This allows geochemists to spatially map the isotope composition in cross-sections of rock samples, a tool which is lost if the rock is digested and introduced as a liquid sample. Lasers for this task are built to have highly controllable power outputs and uniform radial power distributions, to produce craters which are flat bottomed and of a chosen diameter and depth. For both Laser Ablation and Desolvating Nebulisers, a small flow of nitrogen may also be introduced into the argon flow. Nitrogen exists as a dimer, so has more vibrational modes and is more efficient at receiving energy from the RF coil around the torch. Other methods of sample introduction are also utilized. Electrothermal vaporization (ETV) and in torch vaporization (ITV) use hot surfaces (graphite or metal, generally) to vaporize samples for introduction. These can use very small amounts of liquids, solids, or slurries. Other methods like vapor generation are also known.
Watson was retrospectively ruled ineligible for the award by the commission, and the medal then awarded to the next-highest vote-getters, Richmond's Trent Cotchin and then-Hawthorn player Sam Mitchell (who had just been traded to the West Coast Eagles at the time), under the normal rules regarding ineligible players in Brownlow Medal counts. Watson had pre-empted the decision by announcing on 11 November 2016 that he would hand back the medal.
Sources: en.wikipedia.org
=== Immunotherapy === Immunotherapy harnesses the body's immune system to recognize and attack cancer cells or other disease targets. In theranostics, immunotherapeutic approaches can be coupled with diagnostic imaging to assess immune cell infiltration, tumor immunogenicity, and treatment response. Imaging techniques, such as PET and MRI, can provide valuable information about the tumor microenvironment, immune cell dynamics, and response to immunotherapies. Furthermore, theranostic strategies involving the use of radiolabeled immunotherapeutic agents allow for simultaneous imaging and therapy, aiding in patient selection, treatment monitoring, and optimization of immunotherapeutic regimens.
=== Fire hazards === Like other organic compounds, polystyrene is flammable. Polystyrene is classified according to DIN4102 as a "B3" product, meaning highly flammable or "Easily Ignited". As a consequence, although it is an efficient insulator at low temperatures, its use is prohibited in any exposed installations in building construction. It must be concealed behind drywall, sheet metal, or concrete. Foamed polystyrene plastic materials have been accidentally ignited and caused huge fires and losses of life, for example at the Düsseldorf International Airport and in the Channel Tunnel (where polystyrene was inside a railway carriage that caught fire).
== Background == In the late 1970s, tooth adhesion phosphate monomer 2-methacryloyloxethyl phenyl hydrogen phosphate (Phenyl-P) was developed for tooth-saving restoration techniques. 4-Methacryloyloxyethyl trimellitic acid anhydride (4-META) that adheres to not only tooth structures but also dental alloys, was developed almost at the same time. In order to create adhesive monomers having higher performance, investigation and optimization of adhesive monomer molecular structure was carried out. The results of the experiments have provided adhesive monomers with a more suitable chemical structure, and one of those is MDP.
== Corneal cross-linking == In 2002, Hafezi's clinical and research interests turned to the cornea. He became a corneal specialist, and his work helped develop the principles of corneal collagen cross-linking (CXL) and translate CXL from a laboratory into a clinical setting, initially for the treatment of keratoconus. Hafezi's combination of basic science knowledge combined with clinical, surgical experience of CXL has led him to become one of the world's leading experts on both keratoconus and cross-linking technology. The impact of CXL on the treatment of keratoconus is hard to underestimate: today, CXL considered to be the treatment of choice for progressive keratoconus and corneal ectasias, reducing the need for corneal transplantation by half. Hafezi continued to work to expand the number of people who could benefit from CXL. Briefly, the original CXL method, termed the Dresden Protocol, involves removing the central 8–10 mm of the corneal epithelium of adult patients with corneas thicker than 400 μm, and applying 0.1% riboflavin solution to the cornea for 30 minutes before, and at 5-minute intervals during 365 nm UV-A irradiation of the corneal surface at an irradiance of 3 mW/cm2. Hafezi has helped push the boundaries, pioneering CXL in children with keratoconus, the use of hypoosmolar riboflavin solutions to treat people with thin (≤400 μm) corneas. and using CXL to treat post-LASIK ectasia. The knowledge Hafezi accrued from this work led to him becoming a leading international expert on corneal ectasia in general and keratoconus in particular.
Sources: en.wikipedia.org
== External links == "Motixafortide (Code C88309)". NCI Thesaurus. Archived from the original on 18 January 2017. Clinical trial number NCT03246529 for "A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS)" at ClinicalTrials.gov
A concentrated coffee/milk/sugar mixture was produced for the Union army during the American Civil War under the name Essence of Coffee, a teaspoonful of which was mixed with a cup of hot water. It had the consistency of axle grease, and proved so unpopular with the troops that it was soon discontinued. The brand Camp Coffee, a liquid coffee and chicory essence, was first produced in 1876 by Paterson & Sons Ltd in Scotland. The invention for powdered soluble instant coffee was filed on 28 January 1889 and patented in 1890, by David Strang of Invercargill, New Zealand, under patent number 3518, and sold as "Strang's Soluble Coffee Powder", citing the patented "Dry Hot-Air" process. Some modern sources have credited French humorist and writer Alphonse Allais with the invention. The invention had previously been attributed to Satori Kato, a Japanese scientist working in Chicago in 1901. Kato introduced the powdered substance in Buffalo, New York, at the Pan-American Exposition. George Constant Louis Washington developed his own instant coffee process shortly thereafter, and first marketed it commercially (1910). The product was expensive in relation to its quality however, and had the disadvantage of being highly hygroscopic. In the 1938 Nestlé produced a more stable, free-flowing instant coffee powder under the Nescafé brand. It had previously not been possible to spray dry coffee extract due to its high levels of low molecular weight sugars and acids. These cause the spray dried powder to become sticky and clump into a paste.
Since its half-life of 5.5 to 26 hours is quite long, consciousness would take a long time to return. In veterinary medicine, sodium thiopental is used to induce anesthesia in animals. Since it is redistributed to fat, certain lean breeds of dogs such as sighthounds have prolonged recoveries from sodium thiopental due to their lack of body fat. Conversely, obese animals recover rapidly, but it takes much longer for the drug to be entirely removed (metabolized) from their bodies. Sodium thiopental is always administered intravenously, as it can be fairly irritating to tissue and is a vesicant; severe tissue necrosis and sloughing can occur if it is injected incorrectly into the tissue around a vein.
An adrenaline junkie is someone who "has a compulsive desire for extreme excitement". Such activities include extreme and risky sports, substance abuse, unsafe sex, and crime. The term relates to the increase in circulating levels of adrenaline during physiological stress. Such an increase in the circulating concentration of adrenaline is secondary to the activation of the sympathetic nerves innervating the adrenal medulla, as it is rapid and not present in animals where the adrenal gland has been removed. Although such stress triggers adrenaline release, it also activates many other responses within the central nervous system reward system, which drives behavioral responses; while the circulating adrenaline concentration is present, it may not drive behavior. Nevertheless, adrenaline infusion alone does increase alertness and has roles in the brain, including the augmentation of memory consolidation.
=== Active site === Eflornithine's suicide inhibition of ODC physically blocks the natural substrate ornithine from accessing the active site of the enzyme (Figure 3). There are two distinct active sites formed by the homodimerization of ornithine decarboxylase. The size of the opening to the active site is approximately 13.6 Å. When these openings to the active site are blocked, there are no other ways through which ornithine can enter the active site. During the intermediate stage of eflornithine with PLP, its position near Cys-360 allows an interaction to occur. As the phosphate of PLP is stabilized by Arg 277 and a Gly-rich loop (235–237), the difluoromethyl group of eflornithine is able to interact and remain fixated to both Cys-360 and PLP prior to transimination. As shown in the figure, the pyrroline ring interferes with ornithine's entry (Figure 4). Eflornithine will remain permanently bound in this position to Cys-360. As ODC has two active sites, two eflornithine molecules are required to completely inhibit ODC from ornithine decarboxylation.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.